Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Rashida A. Karmali"'
Autor:
Elizabeth Garrett-Mayer, Ingo K. Mellinghoff, Lisa M. DeAngelis, Katharine McNeill, Thomas Kaley, Timothy A. Chan, Robert Terziev, Cameron Brennan, Malbora Manne, Andrew Caterfino, Eli L. Diamond, Debyani Chakravarty, Robert J. Young, Rashida A. Karmali, Michael Lamson, Kathryn Beal, Greg Gorman, Philip H. Gutin, Viviane Tabar, Alissa A. Thomas, Mariza Daras, Elena Pentsova, Linda M Bavisotto, Antonio Omuro, Krishna Patel, Andrew T. McKeown, Xuling Lin, I. T. Gavrilovic
Purpose Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non–voltage-dependent calcium channels with modulatory effects in multiple cell-signaling pathways and synergistic effects with temozolomide (TMZ) in glioblastoma (GBM) models.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cfbf598d8c80172c56f3a3f7431108d
https://europepmc.org/articles/PMC5993168/
https://europepmc.org/articles/PMC5993168/
Autor:
Alan Sandler, Antonio Omuro, Greg Gorman, Walter J. Urba, Matthew H. Taylor, Rashida A. Karmali
Publikováno v:
Journal of Cancer Therapy. :322-333
Pre-clinical studies suggest carboxyamidotriazole orotate (CTO) demonstrates anti-tumor activity through modulation of multiple tyrosine kinase signaling pathways and interactions with the tumor microenvironment. We determined the safety and tolerabi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06f691739381c3a4ca737f78a70e8cd0
https://doi.org/10.4236/jct.2015.64035
https://doi.org/10.4236/jct.2015.64035
Publikováno v:
Journal of Cancer Therapy. :427-441
Background: Doxorubicin (DOX) is an effective treatment for many cancers across the age spectrum, but its therapeutic potential is limited because of dose-dependent relation to both progressive and irreversible cardiomyopathy leading to congestive he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e87ba09a7ee8fa708ae43045b97363ed
https://doi.org/10.4236/jct.2014.55049
https://doi.org/10.4236/jct.2014.55049
Publikováno v:
Journal of Cancer Therapy. :857-871
Background: Paclitaxel (PTX) is approved for the treatment of refractory ovarian cancer and breast cancer, but is problematic due to severe, dose-dependent, potentially irreversible neurotoxicity. Alternative formulations using nanoparticles and lipo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::877ae2268150f680ecf4627f3e6eee9b
https://doi.org/10.4236/jct.2013.44098
https://doi.org/10.4236/jct.2013.44098
Autor:
Elena Pentsova, Linda M Bavisotto, Malbora Manne, Xuling Lin, Mariza Daras, Igor T. Gavrilovic, Antonio Omuro, Lisa M. DeAngelis, Jessica Hansen, Thomas Kaley, Ingo K. Mellinghoff, Andrew T. McKeown, Greg Gorman, Michael Lamson, Rashida A. Karmali
Publikováno v:
Journal of Clinical Oncology. 34:2064-2064
2064Background: CTO is an oral inhibitor of non-voltage-dependent calcium signaling that results in simultaneous modulation of several receptor-mediated calcium-dependent signaling pathways. This s...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba16e2223ae05a853f76a279e4307e3c
https://doi.org/10.1200/jco.2016.34.15_suppl.2064
https://doi.org/10.1200/jco.2016.34.15_suppl.2064
Autor:
Katharine McNeill, Lisa M. DeAngelis, Antonio Omuro, Robert J. Young, Thomas Kaley, Michael Lamson, Kathryn Beal, Barry Douglas Anderson, Alissa A. Thomas, Ingo K. Mellinghoff, Brandon Burch, Timothy A. Chan, Eli L. Diamond, Julio Arevalo Perez, Rashida A. Karmali, Yoshiya Yamada
Publikováno v:
Journal of Clinical Oncology. 34:2060-2060
2060Background: CTO is an oral inhibitor of non-voltage-dependent calcium signaling achieving simultaneous modulation of several receptor-mediated signaling pathways. A single-agent phase I trial d...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9e2d678715be6aaca9fcc561627b184
https://doi.org/10.1200/jco.2016.34.15_suppl.2060
https://doi.org/10.1200/jco.2016.34.15_suppl.2060
Publikováno v:
Journal of Solid Tumors. 2
Background: Carboxyamidotriazole orotate (CTO) is the orotic acid salt of 5-amino-1(4-(4-chlorobenzoyl)-3, 5-dichlorobenzyl)-1, 2, 3-triazole-4-carboxamide (CAI). CTO possesses increased solubility as compared to CAI as the free base. The antiprolife
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8eee7b5d1bdd34a63a29154ee923c5b
https://doi.org/10.5430/jst.v2n5p13
https://doi.org/10.5430/jst.v2n5p13
Autor:
Robert J. Young, Rajiv Magge, Elena Pentsova, Lisa M. DeAngelis, Ingo K. Mellinghoff, Kyung K. Peck, Julio Arevalo Perez, Antonio Omuro, Thomas Kaley, Greg Gorman, Eli L. Diamond, Rashida A. Karmali, Barry Anderson, Sean McLean
Publikováno v:
Neuro-Oncology. 16:v150-v151
BACKGROUND: Advanced imaging techniques have been proposed as potentially useful tools for evaluation of biological effects of new targeted agents. CTO is an oral inhibitor of non-voltage-dependent calcium signaling that modulates several pathways, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c6a1230bbaaa01653a05c2c4b504fea
https://doi.org/10.1093/neuonc/nou264.55
https://doi.org/10.1093/neuonc/nou264.55
Autor:
Woody Massey, James E. Herndon, Patrick Healy, Gordana Vlahovic, Rashida A. Karmali, Elizabeth Miller, Susan Boulton, Dina Randazzo, Annick Desjardins, Eric S. Lipp, Katherine B. Peters, Henry S. Friedman
Publikováno v:
Journal of Clinical Oncology. 33:2067-2067
2067 Background: BEV is approved for the treatment of recurrent glioblastoma pts, but there is a lack of effective therapies once a tumor recurs on BEV. CTO, an oral inhibitor of non-voltage-depend...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b4f49717983b89b7808e18a85e5a810
https://doi.org/10.1200/jco.2015.33.15_suppl.2067
https://doi.org/10.1200/jco.2015.33.15_suppl.2067
Autor:
Patrick Healy, Rashida A. Karmali, James E. Herndon, Gordana Vlahovic, Katherine B. Peters, Elizabeth Miller, Henry S. Friedman, Susan Boulton, Annick Desjardins, Sarah Woodring, Eric S. Lipp, Dina Randazzo
Publikováno v:
Journal of Clinical Oncology. 33:e13004-e13004
e13004 Background: CTO is an oral inhibitor of non-voltage-dependent calcium signaling, which modulates several pathways (EGFR, MEK, RAS, HDAC, HSP90, WNT/B-catenin, Akt, ERK, VEGF, Bcr-Abl). We po...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07aaa9e84dc9a1a989c2d0c59e09b35d
https://doi.org/10.1200/jco.2015.33.15_suppl.e13004
https://doi.org/10.1200/jco.2015.33.15_suppl.e13004